WeWork 85 Broad Street 30th Floor (Penthouse), NY NY 10004
Over the past year, NYCHBL has examined the future of clinical trials generally and from the patient perspective. Now we want to delve into one more critical area – breaking down the data silos that often hamper progress. FDA Commissioner Scott Gottlieb recently discussed the agency’s POV on the subject and pointed out:
“New streams of real world data (RWD) gathered from electronic health records (EHRs), lab tests, wearable devices, insurance claims, and even social media can provide important evidence on product safety and effectiveness in settings or populations that may be very different than the information gleaned from registration trials used for approval. This isn’t an indictment of the randomized controlled trial. Far from it. It’s a recognition that new approaches and new technologies can help expand the sources of evidence that we can use to make more reliable treatment decisions. And it’s a recognition that this evidence base can continue to build and improve throughout the therapeutic life of an FDA approved drug or medical device.
During our discussion with leading life sciences organizations, we will examine how they are incorporating Real World Data and Real World Evidence into their clinical trials process to drive better drug development.
NOTE: We have changed our registration process, all Patrons, Corporate Members & Sponsors of NYCHBL will now receive a special access code to register. If you have not received a code, please email us at firstname.lastname@example.org. All Entrepreneur and Executive Members should register at the “Member” discounted rate of $25.
6:00-7:00 pm – Networking
7:00-8:00 pm – Panel discussion / Q&A